drugset / Trial / NCT03815630
A Study of PD1 Combined With Dc-cik in the Treatment of Solid Tumors
Phase 0
Unknown
100 enrolled
Allife Medical Science and Technology Co., Ltd.
Beijing Hospital · collabHenan Provincial People's Hospital · collabThe First People's Hospital of Yunnan · collab
NaSingle-groupOpen-labelHealth-services research
Summary
This is a single center、single arm、open-label, to investigate the safety and efficacy of PD-1 and DC-CIK with anti-solid tumor
Timeline
- Start
- 2019-02-01
- Primary completion
- 2020-02-01
- Completion
- 2021-02-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CIK cells | Cell therapy | 1.5e+09 cells | — |
| Subject | DC cells | Cell therapy | 6e+07 cells | — |
| Subject | Pembrolizumab | Monoclonal antibody | 10 ml | — |